Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Phase I NCT06649110

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) — Recruiting • Phase I • Respiratory /…

📅 29 Apr 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Phase I
NCT ID
NCT06649110
Sponsor
Novartis Pharmaceuticals
Start
2024-10-24
ClinicaliQ Trial Snapshot
  • A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) — Recruiting • Phase I • Respiratory / COPD / Asthma • NCT06649110.
  • What is being tested: LTP001 is a novel investigational treatment being evaluated in a two-part study: Part A assesses safety and tolerability in healthy volunteers, while Part B evaluates efficacy and safety in patients with pulmonary arterial hypertension (PAH).
  • Patient eligibility overview: Part A enrolls healthy adult participants with normal cardiac and pulmonary function; Part B recruits patients with confirmed PAH diagnosis, typically requiring stable disease status and specific haemodynamic criteria to ensure homogeneous study populations.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)

Eligibility Snapshot
  • Part A Inclusion Criteria: * Healthy males and non-child-bearing potential females Part A

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
RSV vaccination: expansion of eligibility to older adults in certain clinical risk groups
Respiratory / COPD / Asthma · NHS England · 01 Jul 2026
From September 2026, RSV vaccination eligibility expands beyond the current age-based criteria to include older adults in specific clinical risk groups, requiring…
View brief →
Clinical Brief
What is postpartum psychosis and why is it central in the Lindsay Clancy trial?
Respiratory / COPD / Asthma · BBC Health · 19 Aug 2026
Postpartum psychosis is a rare but severe psychiatric emergency occurring in 1-2 per 1,000 deliveries, characterised by delusions, hallucinations, and disorganised thinking…
View brief →
Guideline
UK Achondroplasia Network’s consensus guideline for multidisciplinary care of children and young people with achondroplasia: NICE review
Respiratory / COPD / Asthma · 19 May 2026
Establish multidisciplinary team review at diagnosis and at key developmental stages (infancy, pre-school, school age, adolescence) to monitor for complications including spinal…
View guideline →
Clinical Brief
First drug to delay onset of type 1 diabetes made available on NHS
Respiratory / COPD / Asthma · BBC Health · 22 Jun 2026
Teplizumab, an immunotherapy, is now available on the NHS as the first disease-modifying treatment to delay type 1 diabetes onset by approximately…
View brief →
Clinical Brief
Amiodarone: reminder of risks of treatment and need for patient monitoring and supervision
Respiratory / COPD / Asthma · MHRA · 20 May 2026
Amiodarone carries serious risks of pulmonary, hepatic, and thyroid toxicity requiring regular patient monitoring and supervision throughout treatment Healthcare professionals must ensure…
View brief →
Clinical Brief
Amiodarone: reminder of risks of treatment and need for patient monitoring and supervision
Respiratory / COPD / Asthma · MHRA · 20 May 2026
Amiodarone carries serious risks of pulmonary, hepatic, and thyroid toxicity requiring baseline assessment and regular monitoring throughout treatment Patients on amiodarone require…
View brief →